Opinion|Videos|September 23, 2024
Contemporary Guidelines for CRM Conditions
Key Takeaways
- Professional organizations have developed guidelines to manage the interconnectivity of CRM conditions, reflecting advancements in understanding cardiovascular, renal, and metabolic health.
- Recent updates in guidelines include the integration of novel therapeutic agents and personalized treatment strategies, enhancing evidence-based practices.
Key opinion leaders review current guidelines for cardiometabolic conditions, emphasizing recent advancements in the field.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How do guidelines from professional organizations, including ACC, AHA, ADA, KDIGO, ACE, and DCRMi, address the management and interconnectivity of CRM conditions?
- How have these guidelines evolved in recent years? What are the notable guideline updates in recent years?
- What impact have these guidelines had on the treatment outcomes of patients with CRM conditions?
- What gaps are there in these guidelines regarding the management of CRM conditions?
This activity is supported by Boehringer Ingelheim Pharmaceuticals Inc. and Eli Lilly and Company who provided financial support for this program.
Advertisement
Related to this article
Insmed launches once-daily brensocatib in Japan, the country's only approved treatment for noncystic fibrosis bronchiectasis.
Cross-ancestry GWAS of more than 1.8 million people flags SERPINA1, SMAD3, and other bronchiectasis targets shared with COPD and chronic bronchitis.
The FDA approved bepirovirsen, the first antisense oligonucleotide for chronic hepatitis B, offering a new treatment with functional cure potential.
ALIS added to azithromycin and ethambutol raised culture conversion in new MAC lung disease, with rare resistance, in an ENCORE analysis at IDWeek 2026.
Insmed’s once-daily TPIP prodrug shows sustained lung vasodilation in PAH and PH-ILD, improving walk distance and other key measures.
Cosibelimab received an NCCN Category 2A preferred designation for locally advanced CSCC, supported by durable responses and low immune toxicity.
ASPEN links green sputum to neutrophils and exacerbations; brensocatib (DPP1) lowers purulence, while meta-analysis supports fewer flare-ups in bronchiectasis.
Experts at CHEST 2026 urge pulmonologists to keep lung cancer in mind for younger patients who never smoked, to order screening and biomarker testing themselves, and to advocate for patients' access to care.
Advertisement
Advertisement
Trending on AJMC
1
Bepirovirsen Approval Offers New Option for Chronic HBV Treatment
2
Inhaled Amikacin Raises Culture Conversion in New MAC Lung Disease
3
Uninsured Rate Rises to 11.2% as Coverage Erodes Before Medicaid Cuts
4
Bronchiectasis GWAS Highlights Candidate Targets Shared With COPD
5